InflaRx's Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)
Stock Information for InflaRx N.V.
Loading
Please wait while we load your information from QuoteMedia.